Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Metabolic disorder of ms

481 views

Published on

for preclinic medical student

Published in: Health & Medicine
  • Be the first to comment

Metabolic disorder of ms

  1. 1. Metabolic and regulatory disorders of musculoskeletal system อ.นพ.สุวิทยา เธียรประธาน สานักวิชาแพทยศาสตร์
  2. 2. Objective • Gout • Pseudogout • Muscular dystrophy
  3. 3. Gouty arthritis
  4. 4. Epidemiology • Primary gout = 1.7 : 100,000 / year • Age < 50 yr.  M > F • Age > 50 yr.  M < F • BMI, Diet, Alcohol, diuretic drug, Lead poisoning
  5. 5. Purine metabolism
  6. 6. Pathogenesis
  7. 7. Clinical manifestation 1. Asymptomatic hyperuricemia 2. Acute gouty arthritis 3. Intercritical gout 4. Chronic gout  tophi
  8. 8. Diagnosis • Gold standard : Joint fluid aspiration Polarizing Microscope • Lab : serum uric acid level, CBC, ESR, CRP
  9. 9. Radiographic study • Useful for chronic tophaceous gout • seagull wing sign
  10. 10. Differential diagnosis • Pseudogout (CPPD) • Septic arthritis
  11. 11. Associated disease • Renal disease : Chronic urate nephropathy, Acute uric acid nephropathy, Uric acid nephrolithiasis • Metabolic syndrome : Hypertension, Obesity, Hyperlipidemia, Insulin resistance, Coronary heart disease, Stroke, peripheral artery disease, Congestive heart disease
  12. 12. Acute gouty arthritis Single joint Oligo-polyarticular joint Intra-articular steroid injection or NSAIDs or Colchicine Renal or hepatic disease Normal renal and liver function NSAIDs Colchicine 0.6 mg * 3 Prednisolone 30-60 mg/day then Taper off in 2 wks. Taking oral medications Unable Able Solumedrol IM, IV 100-150 mg/d * 1-2 days Or ACTH SC, IM, IV 25-40 IU q 12 hrs * 1-3 days High risk for cardiac or GI toxicity Low risk for cardiac or GI toxicity
  13. 13. Antihyperuricemic therapies • Uricostatic drugs : Allopurinol*, Oxypurinol, Febuxostat • Uricolytic drugs : Uricase • Uricosuric drugs : Probenecid**, Benzbromarone, Sulfinpyrazole***, Losartan, Fenofibrate, Atorvastatin
  14. 14. Controversy • Asymptomatic hyperuricemia • Criteria for treatment : 1. At least two gout attacks/ year 2. Chronic tophi 3. Coexisting illnesses ex. Nephrolithiasis
  15. 15. Chronic tophi treatment • **Do not excision** • Biopsy only to confirm diagnosis • Check urine uric acid level 24 hr : Urate overproduction Vs Urate underexcretion • Control serum uric acid level < 5 mg/dL
  16. 16. ACR recommendation 2012
  17. 17. Pseudogout
  18. 18. Definition • CPPD (Calcium Pyrophosphate Dihydrate) Crystal Deposition Disease • Acute form of disease
  19. 19. Common Clinical Presentations
  20. 20. Clinical setting • Elderly age over 55 years • Mimic to gout • large joint, most often the knee • less often the wrist or ankle • provoked by minor trauma or intercurrent medical or surgical conditions including pneumonia, myocardial infarction, cerebrovascular accident, and pregnancy. • Parenteral G-CSF, Bisphosphanate
  21. 21. Natural history • Chronic case turn to Chondrocalcinosis
  22. 22. Pathogenesis • The loose avascular connective tissue matrices of articular hyaline cartilage, fibrocartilaginous menisci, and of certain ligaments and tendons are particularly susceptible to pathologic calcification. • ANKH is clearly implicated in the pathogenesis of familial and idiopathic/sporadic chondrocalcinosis
  23. 23. Diagnosis • Same as Gout • Positive birefringent • Lab : CBC, ESR, CRP • X-ray for chronic case
  24. 24. Differential diagnosis • Gout • Septic arthritis • Other crystal arthropathy • Chronic case  Rheumatoid arthritis
  25. 25. Treatment
  26. 26. Muscular dystrophy
  27. 27. Introduction • Progressive muscle weakness • Genetic disease • Effect Dystrophin • Duchenne Muscular dystrophy : Most common • Becker Muscular dystrophy : Second most common
  28. 28. Duchene muscular dystrophy • Most common • Male • 1:3500 live male birth • 1/3 new mutation • 65% family history • Onset : age 3-6 years • Pseudohypertrophy of calf muscles Meyeron sign
  29. 29. Diagnosis • Gait • Gower’s sign • Meyeron sign • Macroglossia • Myocardial deterioration • IQ ~ 80 • Increase CPK (200x) • Myopathic change in EMG Bx: muscle degeneration • Immunoblotting: Absence dystrophin • DNA mutation analysis
  30. 30. Natural history • Progress slowly and continuously • muscle weakness – lower --> upper extremities • unable to ambulate: 10 year (7-12) • death from pulmonary/ cardiac failure: 2-3rd decade
  31. 31. Treatment • Supportive treatment : Cardiology, Respiratory • Prednisolone 0.75 mg/Kg/day • Surgery required to stabilize skeletal structure : Scoliosis • Counseling family for another child • Specific treatment : PTC 124 *, PRO051**

×